越南肺炎鏈球菌疫苗市場評估:依疫苗類型,疫苗特性,給藥途徑,年齡層,最終用戶,分銷管道和地區劃分的機會和預測（2017-2031）

越南肺炎鏈球菌疫苗市場規模將從2023年的1.1億美元成長到2031年的1.8,829億美元，預計2024-2031年期間複合年增長率為8.23%。

由於多種因素的影響，越南的肺炎球菌疫苗市場正在強勁增長，包括疫苗接種計劃意識的提高、肺炎球菌疾病發病率的上升以及老年人口的增加，而老年人口特別容易受到嚴重感染。此外，政府和國際衛生組織在加強免疫計畫和實施減輕肺炎球菌疾病負擔的措施方面發揮積極作用，支持擴大越南肺炎球菌疫苗市場。

越南肺炎鏈球菌疫苗市場受到肺炎發病率上升的顯著影響。肺炎主要影響易感人群，例如兒童、老年人和免疫系統較弱的人。由於盛行率不斷上升，目前正積極進行宣傳活動。此外，由於製藥公司和研究機構為肺炎球菌疾病提供綜合治療的努力，越南的肺炎球菌疫苗市場顯示出顯著的進步和創造力。由於技術的發展和醫療保健基礎設施支出的增加，肺炎球菌疫苗的可用性和可近性已顯著改善。

此外，政府計劃以及與全球衛生組織的合作夥伴關係正在顯著影響越南肺炎球菌疫苗市場的成長。在積極的免疫計劃和戰術夥伴關係的推動下，疫苗接種率不斷提高，大眾對肺炎球菌疾病的認識不斷提高。

肺炎盛行率高：

越南兒童肺炎盛行率位居前15名。這種呼吸道疾病是越南兒童醫院住院的主要原因。在越南，導致 5 歲以下兒童罹患重症肺炎的危險因子有很多，包括營養不良、母乳哺育不足、免疫接種不足、出生體重過低、室內污染和居住條件過度擁擠。

技術進步推動市場：

技術進步是越南肺炎鏈球菌疫苗市場快速成長的原因。肺炎球菌疫苗接種最初是使用基於全細胞的技術開發的。其中包括為患者接種一種熱滅活的 1 型血清細菌，這種細菌一直困擾著南非礦工。然而，MacLeod 等人的研究表明，用莢膜多醣進行免疫可以預防這種疾病，因此在疫苗製劑中使用了純莢膜多醣。目前使用的肺炎鏈球菌疫苗是源自少數最常引起人類疾病的血清型的純莢膜多醣。大多數許可機構目前批准兩種類型的含有莢膜多醣的疫苗。一種是 PPSV，一種是 PCV。這些疫苗配方為越南肺炎鏈球菌疫苗市場的成長做出了重大貢獻。

本報告調查了越南肺炎球菌疫苗市場，並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構、影響市場增長的因素分析以及案例研究。公司簡介等

目錄

第一章研究方法論

第二章 專案範圍與定義

第 3 章執行摘要

第四章 越南肺炎鏈球菌疫苗市場前景

• 市場規模/預測
• 依疫苗類型
  • 減毒活疫苗
  • 滅活疫苗
  • 亞單位疫苗
  • 重組疫苗
• 依疫苗特性
  • 佐劑
  • 非佐劑
• 依給藥途徑
  • 肌肉內
  • 皮下
  • 皮內
  • 其他
• 依年齡
  • 嬰兒
  • 孩子
  • 成人
• 依最終用戶
  • 醫院
  • 專科診所
  • 居家護理
  • 其他
• 依分銷渠道
  • 醫院
  • 零售藥店
  • 網上藥店
  • 非政府組織
• 依地區
  • 北方
  • 南部
  • 中部
• 依公司劃分的市場佔有率

第 5 章 市場測繪

• 依疫苗類型
• 依疫苗特性
• 依給藥途徑
• 依年齡
• 依最終用戶
• 依分銷渠道
• 依地區

第六章 宏觀環境與產業結構

• 供需分析
• 進出口分析
• 價值鏈分析
• PESTEL 分析
• 波特五力分析

第七章市場動態

• 生長促進因子
• 生長抑制因素（問題/限制）

第八章 監理框架與創新

• 臨床試驗
• 專利情況
• 監管審批
• 創新/新興技術

第九節 主要公司狀況

• 前 5 名市場領導者的競爭矩陣
• 前 5 名市場領導者的市場收入分析
• 併購/合資（如適用）
• SWOT分析（5家參與企業）
• 專利分析（如果適用）

第10章價格分析

第11章案例研究

第十二章 主要公司展望

• Pfizer Inc.
• Merck & Co., Inc.
• Walvax Biotechnology Co. Ltd.
• GlaxoSmithKline PLC.
• PnuVax Incorporated
• Novartis AG
• Serum Institute of Vietnam Pvt. Ltd.
• Panacea Biotec Limited
• Shenzhen Kangtai Biological Products Co., Ltd
• Sanofi Pasteur SA

第十三章 戰略建議

第14章關於我們公司/免責聲明

Vietnam pneumococcal vaccine market is projected to witness a CAGR of 8.23% during the forecast period 2024-2031, growing from USD 100.01 million in 2023 to USD 188.29 million in 2031. The Vietnam pneumococcal vaccine market is experiencing robust growth driven by multiple factors, such as an increased awareness of vaccination programs, a rise in pneumococcal disease incidences, and a growing elderly population that is particularly susceptible to severe infections. Additionally, governments and international health organizations are playing an active role in enhancing immunization programs and implementing initiatives to alleviate the burden of pneumococcal diseases, further bolstering the expansion of the Vietnam pneumococcal vaccine market.

The Vietnam pneumococcal vaccine market is significantly impacted by the rising incidence of pneumonia. Pneumonia primarily strikes susceptible populations, including children, the elderly, and those with weakened immune systems. There are now more awareness-raising campaigns because of the rise in instances. Moreover, due to the efforts of pharmaceutical companies and research organizations to provide comprehensive treatments against pneumococcal diseases, the Vietnam pneumococcal vaccine market has seen outstanding progress and creativity. Pneumococcal vaccination availability and accessibility have significantly improved because of technological developments and increased spending on healthcare infrastructure.

Additionally, government programs and alliances with global health organizations have had a big impact on the growth of the Vietnam pneumococcal vaccine market. As proactive immunization programs and tactical partnerships have gained traction, vaccine coverage has grown, and public awareness of pneumococcal illnesses has grown.

High Prevalence of Pneumonia

Vietnam ranks among the top 15 countries with the highest prevalence of child pneumonia. This respiratory condition is a major cause of hospital admissions in pediatric hospitals in Vietnam. Various risk factors contribute to severe pneumonia among children under the age of 5 in Vietnam, including malnutrition, inadequate breastfeeding practices, insufficient vaccinations, low birth weight, indoor pollution, and overcrowded living conditions. The impact of pneumonia on young children in Vietnam is well-documented; however, little is known about the prevalence of severe pneumonia and its risk factors in this age group. Therefore, the primary driver of the Vietnam pneumococcal vaccine market's expansion is the country's high rate of pneumonia cases.

Technological Advancements are Driving the Market

Technological advancements are responsible for the upsurge in the growth of the Vietnam pneumococcal vaccine market. Pneumococcal vaccinations were first developed utilizing whole-cell-based techniques. These entailed immunizing patients with heat-killed serotype 1 bacteria, which had afflicted South African miners. Nonetheless, studies by MacLeod et al. demonstrated that the sickness was prevented by immunization with capsular polysaccharides. Consequently, pure capsular polysaccharides were used in vaccine formulations. It is noteworthy that every pneumococcal serotype has biochemical and antigenic differences. It would be unfeasible to attain universal capsule-based immunization coverage against the hundreds of serotypes that are now in use. Rather, pure capsular polysaccharides from a small number of serotypes that cause human illness most frequently make up the pneumococcal vaccinations that are currently in use. Presently, most licensing agencies approve two types of vaccines containing capsular polysaccharides: one composed of 23 purified capsules (PPSV) and the other composed of 7, 10, or 13 purified capsules conjugated to a protein carrier (PCV). These vaccine formulations are significantly responsible for the growth of the Vietnam pneumococcal vaccine market.

The Demand for Pneumococcal Conjugate Vaccine is on the Rise

The extraordinary impact of the pneumococcal conjugate vaccination (PCV) is substantially responsible for the expansion of the Vietnam pneumococcal vaccine market. PCV is specially designed to boost the immune system's reaction to certain polysaccharides found on the bacteria's surface. These polysaccharides bind to carrier proteins through a process known as conjugation, which greatly improves the immune system's capacity to recognize and successfully fight the infection. Because of its novel architecture, PCV not only boosts immunity but also offers broader protection against a larger variety of pneumococcal serotypes. This transformative vaccine has emerged as a vital tool in reducing the burden of pneumococcal-related diseases and has played a pivotal role in safeguarding public health on a global scale. In 2021, a trial of pneumococcal vaccine schedules for PCV10 and PCV 13 was conducted in Ho Chi Minh City, Vietnam. The trial was sponsored by Murdoch Children's Research Institute, an Australian pediatric medical research institute located in Melbourne, Victoria.

Intramuscular Vaccines are in Great Demand

High demand for intramuscular vaccines is driving the Vietnam pneumococcal vaccine market. Intramuscular vaccinations are preferred due to their ability to elicit a strong immune response. Strong and long-lasting immune system activation is made possible by the muscle tissue's abundant blood supply and greater concentration of antigen-presenting cells. This ultimately results in a notable upsurge in the generation of protective antibodies and cultivates an improved immune memory, both of which are essential for sustained protection against pneumococcal infections. On the other hand, intradermal delivery entails injecting the vaccine into the skin's underlying layer. Although there is evidence to support the usefulness of this method in eliciting a robust and long-lasting immune response for pneumococcal immunization, it is not as well-supported as other vaccines.

Future Market Scenario (2024-2031F)

Vietnam pneumococcal vaccine market will also be influenced by the active role of healthcare organizations in enhancing immunization programs.

The increasing awareness regarding pneumonia disease will propel the growth of the Vietnam pneumococcal vaccine market in the future.

Several products by different companies are in the pipeline which are likely to be launched in coming years. Thus, the availability of new vaccine formulations will drive the growth of the Vietnam pneumococcal vaccine market.

The shift in population demographics toward the geriatric population will cause an increase in the overall number of people with diseases, such as Pneumonia, thereby propelling the market expansion.

Key Players Landscape and Outlook

Over the years, the Vietnam pneumococcal vaccine market has undergone significant changes, spurred by the urgent mission to combat pneumococcal diseases and safeguard public health. Recognizing the gravity of this health challenge, a multitude of pharmaceutical companies, research institutions, and governmental bodies have come to appreciate the importance of working together and consolidating their efforts. In May 2023, Pfizer (Vietnam) Limited Company and Vietnam Vaccine Joint Stock Company entered a memorandum of understanding (MoU) with the shared objective of comprehensive cooperation to safeguard public health, proactively combat diseases, and align with global advancements in healthcare, thereby positively impacting the well-being of the Vietnamese population. The primary focus of this joint project is to improve the proficiency of personnel in the development, implementation, and management of real-world data on vaccination, commonly known as "Real-World Evidence," in Vietnam. By doing so, the collaboration aims to gain valuable insights into vaccination patterns among the Vietnamese people, ensuring the safety and efficacy of vaccination practices.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Vietnam Pneumococcal Vaccine Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Type of Vaccine
  • 4.2.1. Live Attenuated Vaccines
  • 4.2.2. Inactivated Vaccines
  • 4.2.3. Subunit Vaccines
    • 4.2.3.1. Original Pathogen
    • 4.2.3.2. Polysaccharide Vaccine
    • 4.2.3.3. Conjugate Vaccine
    • 4.2.3.4. Protein-based Vaccine
  • 4.2.4. Recombinant Vaccine
• 4.3. By Vaccine Property
  • 4.3.1. Adjuvanted
  • 4.3.2. Non-adjuvanted
• 4.4. By Route of Administration
  • 4.4.1. Intramuscular
  • 4.4.2. Subcutaneous
  • 4.4.3. Intradermal
  • 4.4.4. Others
• 4.5. By Age group
  • 4.5.1. Infants
  • 4.5.2. Children
  • 4.5.3. Adults
• 4.6. By End-user
  • 4.6.1. Hospitals
  • 4.6.2. Specialty Clinics
  • 4.6.3. Homecare
  • 4.6.4. Others
• 4.7. By Distribution Channel
  • 4.7.1. Hospital
  • 4.7.2. Retail Pharmacy
  • 4.7.3. Online Pharmacy
  • 4.7.4. Non-Governmental Organizations
• 4.8. By Region
  • 4.8.1. Northern
  • 4.8.2. Southern
  • 4.8.3. Central
• 4.9. By Company Market Share (%), 2023

5. Market Mapping, 2023

• 5.1. By Type of Vaccine
• 5.2. By Vaccine Property
• 5.3. By Route of Administration
• 5.4. By Age group
• 5.5. By End-user
• 5.6. By Distribution channel
• 5.7. By Region

6. Macro Environment and Industry Structure

• 6.1. Supply Demand Analysis
• 6.2. Import Export Analysis
• 6.3. Value Chain Analysis
• 6.4. PESTEL Analysis
  • 6.4.1. Political Factors
  • 6.4.2. Economic System
  • 6.4.3. Social Implications
  • 6.4.4. Technological Advancements
  • 6.4.5. Environmental Impacts
  • 6.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 6.5. Porter's Five Forces Analysis
  • 6.5.1. Supplier Power
  • 6.5.2. Buyer Power
  • 6.5.3. Substitution Threat
  • 6.5.4. Threat from New Entrant
  • 6.5.5. Competitive Rivalry

7. Market Dynamics

• 7.1. Growth Drivers
• 7.2. Growth Inhibitors (Challenges and Restraints)

8. Regulatory Framework and Innovation

• 8.1. Clinical Trials
• 8.2. Patent Landscape
• 8.3. Regulatory Approvals
• 8.4. Innovations/Emerging Technologies

9. Key Players Landscape

• 9.1. Competition Matrix of Top Five Market Leaders
• 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 9.4. SWOT Analysis (For Five Market Players)
• 9.5. Patent Analysis (If Applicable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

• 12.1. Pfizer Inc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Merck & Co., Inc.
• 12.3. Walvax Biotechnology Co. Ltd.
• 12.4. GlaxoSmithKline PLC.
• 12.5. PnuVax Incorporated
• 12.6. Novartis AG
• 12.7. Serum Institute of Vietnam Pvt. Ltd.
• 12.8. Panacea Biotec Limited
• 12.9. Shenzhen Kangtai Biological Products Co., Ltd
• 12.10. Sanofi Pasteur SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Vietnam Pneumococcal Vaccine Market, By Value, In USD Million, 2017-2031F
• Figure 2. Vietnam Pneumococcal Vaccine Market, By Volume, In Thousand Units, 2017-2031F
• Figure 3. Vietnam Pneumococcal Vaccine Market Share (%), By Type of Vaccine, 2017-2031F
• Figure 4. Vietnam Pneumococcal Vaccine Market Share (%), By Vaccine Property, 2017-2031F
• Figure 5. Vietnam Pneumococcal Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 6. Vietnam Pneumococcal Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 7. Vietnam Pneumococcal Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 8. Vietnam Pneumococcal Vaccine Market Share (%), By Distribution Channel, 2017-2031F
• Figure 9. Vietnam Pneumococcal Vaccine Market Share (%), By Region, 2017-2031F
• Figure 10. By Type of Vaccine Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 11. By Vaccine Property Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 12. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 13. By Age Group Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 14. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 15. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 16. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023